DDReg Pharma- Consulting in regulatory affairs and drug safety

  2026 is shaping up to be a transformative year for pharmacovigilance in the European Union and at the heart of this change is a comprehensive overhaul of the European Medicines Agency’s (EMA) Good Pharmacovigilance Practices (GVP) framework. This isn’t just regulatory housekeeping; it’s a smart modernisation of how drug safety is monitored, analysed, and communicated across the EU. What’s Changing and Why It Matters The EMA has signalled that almost all GVP modules are scheduled for revision in 2026 , spanning core areas such as signal management, risk management plans, inspections, individual case safety reports (ICSRs), and post-authorisation safety studies. These updates are part of a wider push to ensure pharmacovigilance keeps pace with scientific, technological, and data-driven advances in medicine. Key trends emerging from the GVP update schedule include: 🔹 Modernised Signal Detection and Management- Modules such as GVP IX are being updated to reflect more integrate...

  Expanding into highly regulated markets like the European Union and the United Kingdom offers significant commercial opportunities   but it also comes with strict regulatory expectations. Even small gaps in technical documentation, manufacturing data, or submission structure can delay approvals or trigger regulatory queries. This is where regulatory gap analysis becomes essential. Regulatory gap analysis is a systematic review of existing product data, dossiers, and processes to identify discrepancies between what regulators require and what the sponsor currently has. It ensures that clinical, non-clinical, and Chemistry, Manufacturing, and Controls (CMC) information aligns with regional guidelines before submission. Addressing these gaps early helps companies avoid costly rework, delays, and compliance risks. This proactive approach is increasingly important as regulators use structured data reviews and digital tools to identify inconsistencies and deficiencies in submissions. I...

Marketing authorization does not end a medicine’s safety evaluation. Once products enter real-world use, broader patient exposure and long-term treatment can reveal risks not fully identified in clinical trials. Regulators therefore rely on Post-Authorization Safety Studies (PASS) to address post-approval safety uncertainties. PASS are structured pharmacoepidemiological or clinical studies conducted to evaluate identified or potential risks, assess risk-minimization effectiveness, and generate real-world safety evidence. Across the EU, US, UK, and other major markets, mandatory PASS are now embedded in regulatory frameworks and enforced as legally binding obligations. Authorities increasingly assess not only study outcomes, but also protocol governance, reporting discipline, and inspection readiness. As a result, PASS has evolved from a post-approval formality into a critical component of lifecycle pharmacovigilance and approval sustainability. Read in detail here: Post-Authorization S...

  During the evaluation of an Abbreviated New Drug Application (ANDA), the US FDA issued a series of review comments covering multiple sections of the submission. A substantial portion of these comments focused on  Prescribing Information (PI) , reflecting the agency’s heightened expectations for labeling accuracy, internal consistency, and traceability to supporting data. Recognizing the regulatory sensitivity of PI deficiencies and the potential impact on approval timelines, the applicant engaged external regulatory expertise to manage and resolve the observations in a structured and compliant manner. Client Need The applicant required specialized regulatory support to: Interpret and respond to complex US FDA PI-related observations Execute extensive revisions to the Prescribing Information Maintain consistency between PI statements and underlying ANDA data Avoid further rounds of FDA queries or review delays The priority was to achieve  first-cycle closure of PI defici...

In today’s interconnected world, pharmaceutical and medical device companies depend on a complex web of suppliers that span continents. This global expansion unlocks access to specialized materials, niche manufacturing expertise, and operational efficiencies,   but it also introduces heightened regulatory obligations and oversight risks. Regulators no longer tolerate weak supplier control as a siloed or back-office task. Rather, global oversight of supplier compliance and audit processes has become central to quality systems governance,  an essential strategy that protects product quality, safeguards patient safety, and maintains market access. Regulatory Imperatives: Oversight Without Delegation Across major quality frameworks  from ICH Q10 to EU GMP, ISO standards, and the U.S. FDA’s GMP requirements,   the responsibility for supplier performance lies squarely with the product owner. Authorities are clear: manufacturers cannot outsource accountability. Inadequate supplier control fre...

  In the pharmaceutical industry, compliance is not a static destination but a continuous journey of oversight. As regulatory authorities like the FDA, EMA, and MHRA intensify their scrutiny, the robustness of your pharmacovigilance (PV) system becomes your strongest defense. A  Pharmacovigilance Audit Services    is the proactive mechanism that ensures your safety data, processes, and systems are not only compliant but high-performing. DDReg Pharma  provides comprehensive, risk-based audit and compliance services designed to identify gaps before they become regulatory “showstoppers.” Why a “Risk-Based” Audit Strategy is Essential The complexity of modern drug safety—ranging from clinical trial monitoring to post-market surveillance—demands a focused approach.  DDReg Pharma  employs a risk-based audit methodology, prioritizing high-risk areas such as critical safety processes, vendor oversight, and the integrity of the  Pharmacovigilance System Ma...